Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Models for Understanding Resistance to Chemotherapy in Liver Cancer.

Marin JJG, Herraez E, Lozano E, Macias RIR, Briz O.

Cancers (Basel). 2019 Oct 29;11(11). pii: E1677. doi: 10.3390/cancers11111677. Review.

2.

Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters.

Al-Abdulla R, Perez-Silva L, Lozano E, Macias RIR, Herraez E, Abad M, Segues N, Bujanda L, Briz O, Marin JJG.

Biochem Pharmacol. 2019 Oct 24;171:113682. doi: 10.1016/j.bcp.2019.113682. [Epub ahead of print]

PMID:
31669256
3.

Hepatoprotection of Mentha aquatica L., Lavandula dentata L. and Leonurus cardiaca L.

Pereira OR, Macias RIR, Domingues MRM, Marin JJG, Cardoso SM.

Antioxidants (Basel). 2019 Aug 2;8(8). pii: E267. doi: 10.3390/antiox8080267.

4.

Cholangiocarcinoma: State-of-the-art knowledge and challenges.

Banales JM, Cardinale V, Macias RIR, Andersen JB, Braconi C, Carpino G, Alvaro D, Calvisi DF.

Liver Int. 2019 May;39 Suppl 1:5-6. doi: 10.1111/liv.14101. No abstract available.

PMID:
31111668
5.

Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.

Lozano E, Macias RIR, Monte MJ, Asensio M, Del Carmen S, Sanchez-Vicente L, Alonso-Peña M, Al-Abdulla R, Munoz-Garrido P, Satriano L, O'Rourke CJ, Banales JM, Avila MA, Martinez-Chantar ML, Andersen JB, Briz O, Marin JJG.

Hepatology. 2019 Oct;70(4):1246-1261. doi: 10.1002/hep.30656. Epub 2019 May 20.

PMID:
30972782
6.

Mechanisms of Anticancer Drug Resistance in Hepatoblastoma.

Marin JJG, Cives-Losada C, Asensio M, Lozano E, Briz O, Macias RIR.

Cancers (Basel). 2019 Mar 22;11(3). pii: E407. doi: 10.3390/cancers11030407. Review.

7.

Diagnostic and prognostic biomarkers in cholangiocarcinoma.

Macias RIR, Kornek M, Rodrigues PM, Paiva NA, Castro RE, Urban S, Pereira SP, Cadamuro M, Rupp C, Loosen SH, Luedde T, Banales JM.

Liver Int. 2019 May;39 Suppl 1:108-122. doi: 10.1111/liv.14090. Review.

PMID:
30843325
8.

Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses.

Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J, Kohari K, Bacq Y, Bozkurt N, Brun-Furrer R, Bull L, Estiú MC, Grymowicz M, Gunaydin B, Hague WM, Haslinger C, Hu Y, Kawakita T, Kebapcilar AG, Kebapcilar L, Kondrackienė J, Koster MPH, Kowalska-Kańka A, Kupčinskas L, Lee RH, Locatelli A, Macias RIR, Marschall HU, Oudijk MA, Raz Y, Rimon E, Shan D, Shao Y, Tribe R, Tripodi V, Yayla Abide C, Yenidede I, Thornton JG, Chappell LC, Williamson C.

Lancet. 2019 Mar 2;393(10174):899-909. doi: 10.1016/S0140-6736(18)31877-4. Epub 2019 Feb 14. Erratum in: Lancet. 2019 Mar 16;393(10176):1100.

9.

Development and characterization of mouse monoclonal antibodies to eight human complement components: Analysis of reactivity with orthologs of nine mammalian genera.

Monedero M, Infantes-Lorenzo JA, Moreno I, Martín AB, Macias RIR, Toraño A, Domínguez M.

Comp Immunol Microbiol Infect Dis. 2019 Feb;62:7-12. doi: 10.1016/j.cimid.2018.11.008. Epub 2018 Nov 24.

PMID:
30711050
10.

Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.

Al-Abdulla R, Lozano E, Macias RIR, Monte MJ, Briz O, O'Rourke CJ, Serrano MA, Banales JM, Avila MA, Martinez-Chantar ML, Geier A, Andersen JB, Marin JJG.

Br J Pharmacol. 2019 Mar;176(6):787-800. doi: 10.1111/bph.14563. Epub 2019 Feb 11.

PMID:
30592786
11.

Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.

Banales JM, Iñarrairaegui M, Arbelaiz A, Milkiewicz P, Muntané J, Muñoz-Bellvis L, La Casta A, Gonzalez LM, Arretxe E, Alonso C, Martínez-Arranz I, Lapitz A, Santos-Laso A, Avila MA, Martínez-Chantar ML, Bujanda L, Marin JJG, Sangro B, Macias RIR.

Hepatology. 2019 Aug;70(2):547-562. doi: 10.1002/hep.30319. Epub 2019 Feb 14.

12.

Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib.

Macias RIR, Sánchez-Martín A, Rodríguez-Macías G, Sánchez-Abarca LI, Lozano E, Herraez E, Odero MD, Díez-Martín JL, Marin JJG, Briz O.

Oncotarget. 2018 Jun 19;9(47):28474-28485. doi: 10.18632/oncotarget.25494. eCollection 2018 Jun 19.

13.

Role of the placenta in serum autotaxin elevation during maternal cholestasis.

Macias RIR, Matilla S, Lozano E, Estiú MC, Oude Elferink RP, Marin JJG.

Am J Physiol Gastrointest Liver Physiol. 2018 Sep 1;315(3):G399-G407. doi: 10.1152/ajpgi.00112.2018. Epub 2018 Jun 21.

14.

Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition.

Lozano E, Briz O, Macias RIR, Serrano MA, Marin JJG, Herraez E.

J Pers Med. 2018 Apr 16;8(2). pii: E14. doi: 10.3390/jpm8020014. Review.

15.

Molecular bases of the poor response of liver cancer to chemotherapy.

Marin JJG, Briz O, Herraez E, Lozano E, Asensio M, Di Giacomo S, Romero MR, Osorio-Padilla LM, Santos-Llamas AI, Serrano MA, Armengol C, Efferth T, Macias RIR.

Clin Res Hepatol Gastroenterol. 2018 Jun;42(3):182-192. doi: 10.1016/j.clinre.2017.12.006. Epub 2018 Mar 12. Review.

PMID:
29544679
16.

Lactation during cholestasis: Role of ABC proteins in bile acid traffic across the mammary gland.

Blazquez AMG, Macias RIR, Cives-Losada C, de la Iglesia A, Marin JJG, Monte MJ.

Sci Rep. 2017 Aug 7;7(1):7475. doi: 10.1038/s41598-017-06315-8.

17.

The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma.

Macias RIR, Banales JM, Sangro B, Muntané J, Avila MA, Lozano E, Perugorria MJ, Padillo FJ, Bujanda L, Marin JJG.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1468-1477. doi: 10.1016/j.bbadis.2017.08.002. Epub 2017 Aug 4. Review.

18.

Chemoresistance and chemosensitization in cholangiocarcinoma.

Marin JJG, Lozano E, Herraez E, Asensio M, Di Giacomo S, Romero MR, Briz O, Serrano MA, Efferth T, Macias RIR.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1444-1453. doi: 10.1016/j.bbadis.2017.06.005. Epub 2017 Jul 7. Review.

19.

Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.

Arbelaiz A, Azkargorta M, Krawczyk M, Santos-Laso A, Lapitz A, Perugorria MJ, Erice O, Gonzalez E, Jimenez-Agüero R, Lacasta A, Ibarra C, Sanchez-Campos A, Jimeno JP, Lammert F, Milkiewicz P, Marzioni M, Macias RIR, Marin JJG, Patel T, Gores GJ, Martinez I, Elortza F, Falcon-Perez JM, Bujanda L, Banales JM.

Hepatology. 2017 Oct;66(4):1125-1143. doi: 10.1002/hep.29291. Epub 2017 Aug 26.

PMID:
28555885
20.

Relationship between early onset severe intrahepatic cholestasis of pregnancy and higher risk of meconium-stained fluid.

Estiú MC, Frailuna MA, Otero C, Dericco M, Williamson C, Marin JJG, Macias RIR.

PLoS One. 2017 Apr 24;12(4):e0176504. doi: 10.1371/journal.pone.0176504. eCollection 2017.

21.

Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1.

Herraez E, Sanchez-Vicente L, Macias RIR, Briz O, Marin JJG.

Oncotarget. 2017 May 23;8(21):34617-34629. doi: 10.18632/oncotarget.16119.

22.

The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.

Geier A, Macias RI, Bettinger D, Weiss J, Bantel H, Jahn D, Al-Abdulla R, Marin JJ.

Oncotarget. 2017 Feb 28;8(9):15846-15857. doi: 10.18632/oncotarget.15029.

23.

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D.

Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80. doi: 10.1038/nrgastro.2016.51. Epub 2016 Apr 20.

24.

Bile Acids in Physiology, Pathology and Pharmacology.

Marin JJ, Macias RI, Briz O, Banales JM, Monte MJ.

Curr Drug Metab. 2015;17(1):4-29. Review.

PMID:
26526836
25.

Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia.

Marin JJ, Briz O, Rodríguez-Macias G, Díez-Martín JL, Macias RI.

Blood Rev. 2016 Jan;30(1):55-64. doi: 10.1016/j.blre.2015.08.001. Epub 2015 Aug 18. Review.

PMID:
26321049
26.

Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT).

Lozano E, Monte MJ, Briz O, Hernández-Hernández A, Banales JM, Marin JJ, Macias RI.

J Control Release. 2015 Oct 28;216:93-102. doi: 10.1016/j.jconrel.2015.08.022. Epub 2015 Aug 14.

PMID:
26278512
27.

Mechanisms of Resistance to Chemotherapy in Gastric Cancer.

Marin JJ, Al-Abdulla R, Lozano E, Briz O, Bujanda L, Banales JM, Macias RI.

Anticancer Agents Med Chem. 2016;16(3):318-34. Review.

PMID:
26234359
28.

Molecular Bases of Chemoresistance in Cholangiocarcinoma.

Marin JJG, Lozano E, Briz O, Al-Abdulla R, Serrano MA, Macias RIR.

Curr Drug Targets. 2017;18(8):889-900. doi: 10.2174/1389450116666150223121508. Review.

PMID:
25706108
29.

Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the mother-placenta-foetus trio during cholestasis of pregnancy.

Estiú MC, Monte MJ, Rivas L, Moirón M, Gomez-Rodriguez L, Rodriguez-Bravo T, Marin JJ, Macias RI.

Br J Clin Pharmacol. 2015 Feb;79(2):316-29. doi: 10.1111/bcp.12480.

30.

Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.

Macias RI.

ISRN Hepatol. 2014 Feb 16;2014:828074. doi: 10.1155/2014/828074. eCollection 2014. Review.

31.

Role of macrophages in bile acid-induced inflammatory response of fetal lung during maternal cholestasis.

Herraez E, Lozano E, Poli E, Keitel V, De Luca D, Williamson C, Marin JJ, Macias RI.

J Mol Med (Berl). 2014 Apr;92(4):359-72. doi: 10.1007/s00109-013-1106-1. Epub 2013 Dec 7.

PMID:
24317353
32.

The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy.

Marin JJ, Monte MJ, Blazquez AG, Macias RI, Serrano MA, Briz O.

Acta Pharmacol Sin. 2014 Jan;35(1):1-10. doi: 10.1038/aps.2013.131. Epub 2013 Dec 9. Review.

33.

Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development.

Lozano E, Sanchez-Vicente L, Monte MJ, Herraez E, Briz O, Banales JM, Marin JJ, Macias RI.

Mol Cancer Res. 2014 Jan;12(1):91-100. doi: 10.1158/1541-7786.MCR-13-0503. Epub 2013 Nov 19.

34.

Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term.

Keitel V, Spomer L, Marin JJ, Williamson C, Geenes V, Kubitz R, Häussinger D, Macias RI.

Placenta. 2013 Sep;34(9):810-6. doi: 10.1016/j.placenta.2013.06.302. Epub 2013 Jul 10.

PMID:
23849932
35.

Liver metabolic/oxidative stress induces hepatic and extrahepatic changes in the expression of the vitamin C transporters SVCT1 and SVCT2.

Hierro C, Monte MJ, Lozano E, Gonzalez-Sanchez E, Marin JJ, Macias RI.

Eur J Nutr. 2014;53(2):401-12. doi: 10.1007/s00394-013-0536-4. Epub 2013 May 26.

PMID:
23708151
36.

Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.

Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, Banales JM, Marin JJ, Briz O.

Hepatology. 2013 Sep;58(3):1065-73. doi: 10.1002/hep.26425. Epub 2013 Jul 30.

PMID:
23532667
37.

Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy.

Martinez-Becerra P, Monte I, Romero MR, Serrano MA, Vaquero J, Macias RI, Del Rio A, Grañé-Boladeras N, Jimenez F, San-Martin FG, Pastor-Anglada M, Marin JJ.

Pharmacol Res. 2012 Nov;66(5):419-27. doi: 10.1016/j.phrs.2012.07.005. Epub 2012 Aug 8.

PMID:
22898327
38.

No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors.

Martinez-Becerra P, Vaquero J, Romero MR, Lozano E, Anadon C, Macias RI, Serrano MA, Grañé-Boladeras N, Muñoz-Bellvis L, Alvarez L, Sangro B, Pastor-Anglada M, Marin JJ.

Mol Pharm. 2012 Jun 4;9(6):1693-704. doi: 10.1021/mp300028a. Epub 2012 May 1.

PMID:
22524153
39.

Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs.

Marin JJ, Briz O, Monte MJ, Blazquez AG, Macias RI.

Curr Cancer Drug Targets. 2012 May;12(4):402-38. Review.

PMID:
22229248
40.

Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta.

Blazquez AG, Briz O, Romero MR, Rosales R, Monte MJ, Vaquero J, Macias RI, Cassio D, Marin JJ.

Mol Pharmacol. 2012 Feb;81(2):273-83. doi: 10.1124/mol.111.075143. Epub 2011 Nov 17.

PMID:
22096226
41.

Hepatic expression of sodium-dependent vitamin C transporters: ontogeny, subtissular distribution and effect of chronic liver diseases.

Macias RI, Hierro C, de Juan SC, Jimenez F, Gonzalez-San Martin F, Marin JJ.

Br J Nutr. 2011 Dec;106(12):1814-25. doi: 10.1017/S0007114511002273. Epub 2011 Jul 1.

PMID:
21733302
42.

Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3.

Martinez-Becerra P, Briz O, Romero MR, Macias RI, Perez MJ, Sancho-Mateo C, Lostao MP, Fernandez-Abalos JM, Marin JJ.

Mol Pharmacol. 2011 Mar;79(3):596-607. doi: 10.1124/mol.110.069971. Epub 2010 Dec 20.

PMID:
21173039
43.

In vitro inhibition of OATP-mediated uptake of phalloidin using bile acid derivatives.

Herraez E, Macias RI, Vazquez-Tato J, Vicens M, Monte MJ, Marin JJ.

Toxicol Appl Pharmacol. 2009 Aug 15;239(1):13-20. doi: 10.1016/j.taap.2009.04.024. Epub 2009 May 21.

PMID:
19464309
44.

Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity.

Herraez E, Macias RI, Vazquez-Tato J, Hierro C, Monte MJ, Marin JJ.

Toxicol Appl Pharmacol. 2009 Aug 15;239(1):21-8. doi: 10.1016/j.taap.2009.04.017. Epub 2009 May 4.

PMID:
19409403
45.

Excretion of biliary compounds during intrauterine life.

Macias RI, Marin JJ, Serrano MA.

World J Gastroenterol. 2009 Feb 21;15(7):817-28. Review.

46.

Cytosol-nucleus traffic and colocalization with FXR of conjugated bile acids in rat hepatocytes.

Monte MJ, Rosales R, Macias RI, Iannota V, Martinez-Fernandez A, Romero MR, Hofmann AF, Marin JJ.

Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G54-G62. doi: 10.1152/ajpgi.00592.2007. Epub 2008 May 8.

47.

Molecular pathogenesis of intrahepatic cholestasis of pregnancy.

Arrese M, Macias RI, Briz O, Perez MJ, Marin JJ.

Expert Rev Mol Med. 2008 Mar 28;10:e9. doi: 10.1017/S1462399408000628. Review.

PMID:
18371245
48.

Molecular bases of the fetal liver-placenta-maternal liver excretory pathway for cholephilic compounds.

Marin JJ, Macias RI, Briz O, Perez MJ, Blazquez AG, Arrese M, Serrano MA.

Liver Int. 2008 Apr;28(4):435-54. doi: 10.1111/j.1478-3231.2008.01680.x. Review.

PMID:
18339071
49.

Expression, localization, and inducibility by bile acids of hepatobiliary transporters in the new polarized rat hepatic cell lines, Can 3-1 and Can 10.

Cassio D, Macias RI, Grosse B, Marin JJ, Monte MJ.

Cell Tissue Res. 2007 Dec;330(3):447-60. Epub 2007 Oct 2.

PMID:
17909858
50.

Ontogenic development-associated changes in the expression of genes involved in rat bile acid homeostasis.

Cuesta de Juan S, Monte MJ, Macias RI, Wauthier V, Calderon PB, Marin JJ.

J Lipid Res. 2007 Jun;48(6):1362-70. Epub 2007 Mar 1.

Supplemental Content

Loading ...
Support Center